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Abstract
Background: Large-scale case control studies revealed a number of moderate risk - low frequency breast cancer
alleles of the PALB2 and RECQL genes. Some of these were reported as founder variants of Central and Eastern
Europe. Based on highly similar founder variant spectra of the BRCA1 in Poland and Latvia, we decided to test the
frequency of other common variants of moderate breast cancer risk — c.509_510delGA (rs515726124) and c.172_
175delTTGT (rs180177143) of the PALB2 gene and c.1667_1667+3delAGTA variant of the RECQL gene in a breast
cancer case-control series from Latvia to better understand the role of genes in susceptibility to breast cancer and
their clinical significance.
Methods: The case-control study was performed based on an unselected breast cancer case group of 2480 women
and a control group, including 1240 voluntary, to our knowledge unrelated, female donors without reported
oncological disease.
Results: The calculated frequency for c.509_510delGA of the PALB2 gene in the case group is 0.35 and 0.00% in the
control group, with respective relative risk (RR) 7.18 (CI 95% 0.37–138.75; p = 0.19). As for the PALB2 c.172_
175delTTGT variant, the frequency in the case group of our study is 0.04%. In the control group of our study all
individuals were homozygous for the wild-type allele, which lead to calculated RR = 1.50 (CI 95% 0.06–36.83; p-
value = 0.80). There were no carriers of the RECQL variant c.1667_1667+3delAGTA identified in our case group and 2
heterozygotes were identified in the control group. The calculated RR = 0.26 (CI 95% 0.01–5.33; p-value = 0.38).
Conclusion: Results obtained for the PALB2 gene variants are able to supplement evidence on the allele frequency
in breast cancer patients from the region of Central and Eastern Europe. Based on our results we cannot confirm
the contribution of the RECQL variant c.1667_1667+3delAGTA allele to breast cancer development.
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Background
High penetrance breast cancer susceptibility genes —
BRCA1 and BRCA2 are responsible only for 5–10% of
familial breast cancers [1]. Large-scale case control stud-
ies revealed a number of so-called moderate risk breast
cancer alleles. Those can further be subdivided into high
penetrance-low frequency (i.e. TP53, SKT-11, PTEN and
CDH1) and moderate penetrance-low frequency (i.e.
ATM, CHEK2, RAD51 and PALB2) alleles. The preva-
lence of moderate penetrance variants usually varies
among different populations and requires statistical evi-
dence from association studies of breast cancer cases
and population-matched controls [1, 2]. Lately the
RECQL gene is also considered a breast cancer suscepti-
bility gene [3–5]. Many of the genetic variants of the
mentioned genes still lack clinical validation as breast
cancer susceptibility polymorphisms.
The PALB2 (Partner and Localizer of BRCA2) gene
encoding a protein is involved in the intranuclear
stabilization and localization of the BRCA2 protein and
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supports some of its functions in homologous recombin-
ation and double strand break repair. Monoallelic variants
and a heterozygous state are proven to be associated with
a high risk for breast cancer development, almost compar-
able to that of BRCA2 [6]. With a frequency ranging from
0.5 to 1.0% in general breast cancer populations the trun-
cating allelic variants c.509_510delGA (rs515726124) and
c.172_175delTTGT (rs180177143) have recently been
discussed in the region of Central and Eastern Europe -
Poland, Belarus, Germany and Russia [7, 8]. The first
report of c.509_510delGA allele (PALB2) frequency identi-
fied 4 of 648 (0.6%) unrelated familial breast cancer pa-
tients from central Poland [9]. Noskowicz and colleagues
identified the c.509_510delGA allele in 3/1008 (0.3%) Ger-
man breast cancer patients, 2/994 (0.2%) Russian breast
cancer patients and 5/1922 (0.3%) Belarusian breast
cancer patients [7]. In 2015 another group of researchers
from Poland published a large cohort analysis which
showed frequencies of 0.61% for the c.509_510delGA al-
lelic variant and 0.32% for the c.172_175delTTGT, re-
spectively [8]. Clinical significance of the c.509_510delGA
allelic variant based on the ClinVar database is pathogenic;
for the c.172_175delTTGT allelic variant - conflicting in-
terpretations of pathogenicity [10].
As for most established breast cancer susceptibility
genes, RECQL (RECQ1) encodes a protein, functioning
in DNA repair. As part of the RecQ DNA helicase fam-
ily, its role is thought to be DNA unwinding, replication
fork stabilisation and assisting branch migration and
strand annealing [11]. The allelic variant c.1667_
1667+3delAGTA in the RECQL gene is described as a
founder mutation in the studied population from
Poland, with a frequency of 0.23% in the group of unse-
lected breast cancer cases and 0.04% in the control
group with OR = 5.4 [5]. Based on in silico prediction
this allelic variant leads to the splice site change and to
changes in protein level p.K555delinsMYKLIHYSFR
[12]. Recent publications on results for c.1667_
1667+3delAGTA screening in breast cancer patients and
controls from Eastern European and Central European
populations have tried to clarify the exact magnitude of
the risk. The results of a breast cancer case-control
series from Belarus and Germany revealed OR = 1.23
(95% CI 0.44–3.47, p-value = 0.69) [13]. In the study on
the RECQL variants in 427 women affected with breast
or ovarian cancer from southwest Poland and West
Ukraine no heterozygous carrier of the c.1667_1667 +
3delAGTA variant was found [14]. Altogether, the allelic
variant might be considered a moderate-risk breast can-
cer susceptibility allele. Clinical significance of the vari-
ant is uncertain.
Based on highly similar founder variant spectra of
BRCA1 in Poland and Latvia, we decided to test the fre-
quency of other common variants of moderate breast
cancer risk —c.509_510delGA (rs515726124) and c.172_
175delTTGT (rs180177143) of the PALB2 gene, and the
c.1667_1667+3delAGTA variant of the RECQL gene.
The breast cancer case-control series from Latvia was
genotyped to gain information on their frequency as well
as a better understanding of the role of genes in suscep-
tibility to breast cancer and their clinical significance.
Methods
The case-control study was performed based on an un-
selected breast cancer case group, including women who
met the criteria for breast cancer (C-50) according to
the International Classification of Diseases (ICD-10),
and a control group, including voluntary, to our know-
ledge unrelated, female donors without reported onco-
logical disease. The case group consisted of 2480 women
and the control group consisted of 1240, included into
the study between 2008 and 2015. Ages in the breast
cancer group ranged from 24 to 86 years. Ages of the
gender-matched controls ranged from 18 to 92 years. In-
formed consent was obtained from all individual partici-
pants included in the study.
The allelic variant c.509_510delGA of the PALB2 gene
was analysed using the restriction fragment length poly-
morphism (RFLP) method. For amplification of a 322 bp
long target region of exon 4 forward primer 5′- AGTC
CTTTAACCCTGGAGAT-3′ and reverse primer 5′- GG
TTCTGGAGAATCTGGAAG-3′ were used. Restriction
endonuclease DdeI (New England Biolabs, Ipswich, Mas-
sachusetts, USA) recognising the allelic variant sequence
was applied. Acquired fragments were separated in 2.5%
agarose gel.
The target region of the RECQL allelic variant
c.1667_1667 + 3delAGTA was amplified with forward
primer 5′- TATTTCAGTCTGCTAGCTTAGTT-3′ and
reverse primer 5′- TAATAGAAGCAGAGATTTCCAT-
CAT-3′, resulting in a 540 bp fragment which was sub-
jected to restriction endonuclease MspC1 (BIORON
GmbH, Ludwigshafen, Germany) to cut DNA in the
control site and in the case of the wild type allele,
resulting in four fragments. RFLP was analysed in 2.5%
agarose gel.
For analysis of the PALB2 gene allelic variant c.172_
175delTTGT the target PCR product was subjected to
the denaturing high performance liquid chromatography
(DHPLC) method, according to the manufacturers
protocol (Transgenomic Inc., Omaha, NE, USA). All
primers for amplification of target gene regions were de-
signed using NCBI Primer BLAST [15].
All protocols applied to analyse allelic variants were
verified by Sanger sequencing according to the manufac-
turers protocol (Life Technologies, Carlsbad, CA, USA).
Statistical analyses were performed using MedCalc for
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Windows, version 15.0 (MedCalc Software, Ostend,
Belgium).
Results
Three allelic variants of the PALB2 and the RECQL
genes were analysed in the case and control groups.
The calculated frequency for c.509_510delGA of the
PALB2 gene was in line with results from the Belarusian
and German populations, but lower than those reported
in the Polish population, with respective relative risk
(RR) 7.18 (CI 95% 0.37–138.75; p = 0.19) (Table 1). As
for the PALB2 c.172_175delTTGT variant, the frequency
in the case group of our study is significantly lower, as in
the published data from Poland. In the control group of
our study no heterozygous carriers were detected (Table
1), which lead to calculated RR = 1.50 (CI 95% 0.06–
36.83; p-value = 0.80). There were no carriers identified
in our case group and 2 heterozygotes were identified in
the control group (Table 2). The calculated RR = 0.26
(CI 95% 0.01–5.33; p-value = 0.38).
Variant c.1667_1667+3delAGTA of the RECQL gene
reported as founder variant in the Polish population was
also analysed in our study. There were no carriers identi-
fied in our case group and 2 heterozygotes were identi-
fied in the control group (Table 2). The calculated
RR = 0.26 (CI 95% 0.01–5.33; p-value 0.38).
Discussion
The PALB2 gene variants have been identified as breast
cancer susceptibility alleles by previously published
research from Eastern and Central Europe, as well as the
ClinVar database which has classified the c.509_
510delGA allelic variant as pathogenic. Our results are
in concert with previously published findings and indi-
cate c.509_510delGA as a low-frequency variant in the
tested population, which should not be overlooked as a
causative variant in familial breast cancer. The PALB2
c.172_175delTTGT variant was found at very low fre-
quency in the case group. Due to the small number of
analysed cases, the results cannot contribute to the in-
terpretation of variant pathogenicity. However, allele fre-
quency is comparable to that of neighbouring populations,
excluding Poland.
The results for RECQL variant c.1667_1667+3delAGTA
in the control group show comparable frequency to that
reported by Bogdanova et al. [13], and much higher as re-
ported by Cybulski et al. [5]. We did not detect any het-
erozygotes in the case group. Based on the ExAC
database, the frequency of c.1667_1667+3delAGTA is
0.035% [16]. The control group results of Cybulski et al.
are in line with the ExAC database; however, our study re-
sults and those of Bogdanova et al. yielded higher allele
frequencies in the control group. Interestingly, in the Ger-
man and Belarusian populations, the difference between
allele frequency in case and control groups is minimal.
Taking into account the broad age range of our control
group, we cannot exclude the possibility of positive cases
developing disease in later life.
The combined data of the RECQL variant c.1667_
1667+3delAGTA frequency in case-control studies
from Eastern and Central European populations can-
not support assigning this variant to the group of
moderate risk alleles. More case-control study results
from the neighbouring populations are needed to
confirm the impact of this variant on the develop-
ment of breast cancer.
Table 1 Frequency of the PALB2 gene allelic variants in breast cancer patients and controls from Easter European and Central
European populations
Population Polish [9] Polish [8] German [7] Russian [7] Belarusian [7] Latvian
(present study)
Case group
c.509_510delGA 4/648 (0.60%) 76/12529 (0.61%) 3/1008 (0.30%) 2/994 (0.20%) 5/1992 (0.30%) 3/869 (0.35%)
c.172_175delTTGT N/A 40/12529 (0.32%) N/A N/A N/A 1/2479 (0.04%)
Control group
c.509_510delGA 1/1310 (0.08%) 10/4702 (0.21%) 0/2827 (0.00%) 0/891 (0.00%)
c.172_175delTTGT N/A N/A N/A N/A 0/1240 (0.00%)
Table 2 Frequency of the RECQL gene allelic variant in breast cancer patients and controls from Eastern European and Central
European populations
Population Polish [5] Polish and Ukrainian [14] German and Belarusian [13] Latvian (present study)
Case group
c.1667_1667+3delAGTA 30/13136 (0.23%) 0/427 (0.00%) 9/2596 (0.35%) 0/715 (0.00%)
Control group
c.1667_1667+3delAGTA 2/4702 (0.04%) N/A 6/2132 (0.28%) 2/916 (0.22%)
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Conclusion
Results obtained for the PALB2 gene variants are able to
supplement evidence on the allele frequency in breast can-
cer patients from the region of Central and Eastern Europe.
Based on our results we cannot confirm the contribution of
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